Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

C. Shemesh · SciRah

Researcher profile · Semantic Scholar

C. Shemesh

Share profile

C. Shemesh — researcher profile on SciRah

h-index: 16
Works: 39
Citations: 1,174

Most-cited papers

Personalized Cancer Vaccines: Clinical Landscape, Challenges, and Opportunities.
C. Shemesh, Joy Hsu, I. Hosseini, Ben-Quan Shen +4 more
2020Molecular Therapy238 citations Open access
Semantic Scholar
Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 study.
B. Geoerger, C. Zwaan, Lynley V. Marshall, J. Michon +11 more
2019The Lancet Oncology140 citations
Semantic Scholar
Disposition and Pharmacology of a GalNAc3-conjugated ASO Targeting Human Lipoprotein (a) in Mice
R. Yu, M. Graham, Noah M. Post, Stan J. Riney +10 more
2016Molecular Therapy: Nucleic Acids92 citations Open access
Semantic Scholar
Indocyanine green loaded liposome nanocarriers for photodynamic therapy using human triple negative breast cancer cells.
C. Shemesh, Claire W. Hardy, David S. Yu, B. Fernandez +1 more
2014Photodiagnosis and Photodynamic Therapy63 citations
Semantic Scholar
Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2, study.
R. Finn, B.-Y. Ryoo, Chih-Hung Hsu, Da-Neng Li +13 more
2025The Lancet Oncology62 citations Open access
Semantic Scholar
Thermosensitive Liposome Formulated Indocyanine Green for Near-Infrared Triggered Photodynamic Therapy: In Vivo Evaluation for Triple-Negative Breast Cancer
C. Shemesh, Delaram Moshkelani, Hailing Zhang
2015Pharmaceutical Research62 citations
Semantic Scholar
Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform
Andrew H. Ko, Kyu-pyo Kim, J. Siveke, C. Lopez +16 more
2023The Oncologist59 citations Open access
Semantic Scholar
Elucidation of the Biotransformation Pathways of a Galnac3-conjugated Antisense Oligonucleotide in Rats and Monkeys
C. Shemesh, R. Yu, H. Gaus, Sarah Greenlee +9 more
2016Molecular Therapy: Nucleic Acids55 citations Open access
Semantic Scholar
Near-Infrared Image-Guided Delivery and Controlled Release Using Optimized Thermosensitive Liposomes
David C. Turner, Delaram Moshkelani, C. Shemesh, David Luc +1 more
2012Pharmaceutical Research47 citations
Semantic Scholar
Pharmacokinetic and Pharmacodynamic Investigations of ION-353382, a Model Antisense Oligonucleotide: Using Alpha-2-Macroglobulin and Murinoglobulin Double-Knockout Mice
C. Shemesh, R. Yu, H. Gaus, P. Seth +5 more
2016Nucleic Acid Therapeutics40 citations
Semantic Scholar
Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer
C. Shemesh, P. Chanu, K. Jamsen, R. Wada +9 more
2019Journal of Immunotherapy for Cancer38 citations Open access
Semantic Scholar
Pharmacology-based ranking of anti-cancer drugs to guide clinical development of cancer immunotherapy combinations
V. Lemaire, C. Shemesh, Anand Rotte
2021Journal of experimental & clinical cancer research : CR37 citations Open access
Semantic Scholar
Integrated Two‐Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non‐Hodgkin Lymphoma
D. Lu, T. Lu, L. Gibiansky, Xiao-Bin Li +10 more
2019CPT: Pharmacometrics & Systems Pharmacology37 citations Open access
Semantic Scholar
Assessment of the Drug Interaction Potential of Unconjugated and GalNAc3-Conjugated 2′-MOE-ASOs
C. Shemesh, R. Yu, M. S. Warren, Michael Liu +10 more
2017Molecular Therapy: Nucleic Acids34 citations Open access
Semantic Scholar
PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers
R. Kristeleit, A. Leary, A. Oaknin, A. Redondo +12 more
2024British Journal of Cancer27 citations Open access
Semantic Scholar
Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma
C. Shemesh, P. Agarwal, T. Lu, Calvin Lee +7 more
2020Cancer Chemotherapy and Pharmacology16 citations Open access
Semantic Scholar
Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region
C. Shemesh, P. Chan, H. Shao, Derek-Zhen Xu +4 more
2021Liver Cancer14 citations Open access
Semantic Scholar
Early Decision Making in a Randomized Phase II Trial of Atezolizumab in Biliary Tract Cancer Using a Tumor Growth Inhibition‐Survival Modeling Framework
C. Shemesh, P. Chan, M. Marchand, Antonio Gonçalves +6 more
2023Clinical pharmacology and therapy13 citations
Semantic Scholar
Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma
D. Lu, T. Lu, Rong Shi, L. Gibiansky +10 more
2020Pharmaceutical Research13 citations Open access
Semantic Scholar
Atezolizumab Plus Magrolimab, Niraparib, or Tocilizumab in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Randomized Umbrella Study.
A. Drakaki, T. Powles, A. Bamias, J. Martín-Liberal +19 more
2023Clinical Cancer Research11 citations
Semantic Scholar
Safety and efficacy of linvoseltamab as a simplified monotherapy first-line regimen in NDMM: Initial Results from the window of opportunity Phase 1/2 LINKER-MM4 trial
R. Orlowski, Mansi R. Shah, Rajshekhar Chakraborty, P. Fernández‐Abellán +21 more
2025Blood10 citations
Semantic Scholar
Abstract CT185: Assessment of the impact of anti-drug antibodies on PK and clinical outcomes with atezolizumab + bevacizumab in HCC
P. Galle, R. Finn, A. Cheng, C. Bernaards +7 more
2021Clinical Trials8 citations
Semantic Scholar
SO-4 phase Ib/II, open-label, randomised evaluation of atezolizumab plus RO6874281 vs control in MORPHEUS–pancreatic ductal adenocarcinoma
V. Chung, A. Alistar, B. George, Kyu-pyo Kim +11 more
2020Annals of Oncology8 citations Open access
Semantic Scholar
Applying Natural Language Processing to ClinicalTrials.gov: mRNA cancer vaccine case study
Bianca Vora, D. Kuruvilla, Chloe Kim, Michael Wu +2 more
2023Clinical and Translational Science7 citations Open access
Semantic Scholar
Development of a pediatric physiologically-based pharmacokinetic model to support recommended dosing of atezolizumab in children with solid tumors
Wei-Ze Huang, Felix Stader, P. Chan, C. Shemesh +8 more
2022Frontiers in Pharmacology7 citations Open access
Semantic Scholar
Pan‐cancer population pharmacokinetics and exposure‐safety and ‐efficacy analyses of atezolizumab in patients with high tumor mutational burden
C. Shemesh, P. Chan, F. Legrand, D. Shames +7 more
2020Pharmacology Research & Perspectives7 citations Open access
Semantic Scholar
Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + BL-8040 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC).
D. Oh, J. Ajani, Y. Bang, H. Chung +14 more
2020Journal of Clinical Oncology7 citations
Semantic Scholar
Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + PEGPH20 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC).
Andrew H. Ko, Jeeyun Lee, M. Alsina, J. Ajani +16 more
2020Journal of Clinical Oncology6 citations
Semantic Scholar
1315P Phase Ib/II open-label, randomised evaluation of atezolizumab (atezo) + CPI-444 vs docetaxel as second/third-line therapy in MORPHEUS-NSCLC (non-small cell lung cancer)
E. Felip, F. Lim, Martin Johnson, M. O'Brien +16 more
20205 citations Open access
Semantic Scholar
Phase I pharmacokinetic, safety, and preliminary efficacy study of tiragolumab in combination with atezolizumab in Chinese patients with advanced solid tumors
C. Shemesh, Yong-Sheng Wang, A. An, Hao Ding +6 more
2024Cancer Chemotherapy and Pharmacology4 citations Open access
Semantic Scholar
395P Interim analysis (IA) of the giredestrant (G) + ipatasertib (IPAT) arm in MORPHEUS Breast Cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with oestrogen receptor-positive (ER+), HER2-negative, locally advanced/metastatic BC (LA/mBC)
K. Jung, S. Luen, M. Oliveira, J. Sohn +12 more
2023Annals of Oncology3 citations
Semantic Scholar
Pharmacology-based ranking of anti-cancer drugs to guide clinical development of cancer immunotherapy combinations
V. Lemaire, C. Shemesh, Anand Rotte
2021Journal of experimental & clinical cancer research : CR3 citations Open access
Semantic Scholar
Phase Ib/II open-label, randomized evaluation of atezolizumab (atezo) + Imprime PGG (Imprime) + bevacizumab (bev) vs regorafenib (rego) in MORPHEUS: Microsatellite-stable (MSS) metastatic colorectal cancer (mCRC).
M. Fakih, J. Cleary, Yong S. Hong, Tae-You Kim +9 more
2021Journal of Clinical Oncology2 citations
Semantic Scholar
Linvoseltamab (LINVO) Monotherapy in Patients (pts) with Newly Diagnosed (ND) Multiple Myeloma (MM): Initial Dose-Escalation Results from the Window of Opportunity LINKER-MM4 Trial
Christopher J. Ferreri, Mansi R. Shah, Rajshekhar Chakraborty, D. Stevens +6 more
2025Clinical Lymphoma, Myeloma & Leukemia1 citations
Semantic Scholar
Abstract P4-07-23: Preliminary safety in the inavolisib + fulvestrant + ribociclib/abemaciclib arms of MORPHEUS-pan breast cancer: A Phase 1b/2 study of efficacy & safety of multiple treatment combinations in patients with metastatic/locally advanced breast cancer
S. Loi, H. Martin, Mafalda Oliveira, J. Soong +7 more
2025Clinical Cancer Research1 citations
Semantic Scholar
Near-Infrared Image-Guided Delivery and Controlled Release Using Optimized Thermosensitive Liposomes
David C. Turner, Delaram Moshkelani, C. Shemesh, David Luc +1 more
2012Pharmaceutical Research1 citations
Semantic Scholar
Abstract CT266: Chinese race and origin have no clinically meaningful effect on tiragolumab and atezolizumab pharmacokinetics and safety in patients with advanced solid tumors
C. Shemesh, Yongsheng Wang, Andrew An, Hao Ding +6 more
2023Cancer Research0 citations
Semantic Scholar
iMATRIX-Atezolizumab, a Phase 1/2 Study of the Safety, Pharmacokinetics, and Activity of Atezolizumab in Paediatric/Young Adult Patients with Previously Treated Solid Tumours
B. Geoerger, C. Zwaan, L. Marshall, J. Michon +11 more
2019Social Science Research Network0 citations
Semantic Scholar
Thermosensitive Liposome Formulated Indocyanine Green for Near-Infrared Triggered Photodynamic Therapy: In Vivo Evaluation for Triple-Negative Breast Cancer
C. Shemesh, Delaram Moshkelani, Hailing Zhang
2014Pharmaceutical Research0 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

Benjamin Wu×6
Invite
Benjamin Wu — researcher profile on SciRah
S. Allen×6
Invite
S. Allen — researcher profile on SciRah
P. Chan×6
Invite
P. Chan — researcher profile on SciRah
S. Girish×5
Invite
S. Girish — researcher profile on SciRah

×5

Invite

Hailing Zhang — researcher profile on SciRah

Invite

Jin Y. Jin — researcher profile on SciRah

Gianluca Rossato×4

Invite

Gianluca Rossato — researcher profile on SciRah

Invite

R. Yu — researcher profile on SciRah

Yanfeng Wang×4

Invite

Yanfeng Wang — researcher profile on SciRah

Invite

S. Henry — researcher profile on SciRah

Delaram Moshkelani×4

Invite

Delaram Moshkelani — researcher profile on SciRah

N. Al-Sakaff×4

Invite

N. Al-Sakaff — researcher profile on SciRah